Effects of rosuvastatin on pentraxin 3 level and platelet aggregation rate in elderly patients with acute myocardial infarction undergoing elective interventional therapy: a double-blind controlled study.
To investigate clinical effects of rosuvastatin on blood lipid levels, hemorheological profiles, vascular endothelial function, pentraxin 3 (PTX-3) level, the number of granule membrane glycoprotein (GMP-140) molecules and platelet aggregation rate in elderly patients with acute myocardial infarction (AMI) undergoing elective percutaneous coronary intervention (PCI). Total of 120 elderly patients admitted with AMI undergoing elective PCI from July 2014 to January 2016 were selected. The patients were divided into the control group and the experimental group based on the rule of random number generation and double-blind controlled trial, 60 cases in each group. All of 120 patients were treated with routine medications; the experimental group was orally administered with rosuvastatin 1 week before PCI. Blood lipid levels, hemorheological profiles, vascular endothelial function, PTX-3, the number of GMP-140 molecules and platelet aggregation rate were compared between two groups before treatment with rosuvastatin and 10d after elective PCI. Triglycerides, plasma total cholesterol, and low-density lipoprotein levels were significantly lower (p<0.05) in the experimental group when compared with the control group; plasma viscosity, fibrinogen, the viscosity of blood in the high shear rates and in the low shear rates in the experimental group were significantly lower than those of the control group (p<0.05); FMD and NMD in the experimental group were significantly higher than those of the control group (p<0.05); ET-1, TXA2 levels in the experimental group were lower, however, PGI2, NO as well as NOS in the experimental group were higher, when compared the control group, the differences were statistically significant (p<0.05); PTX-3, the number of GMP-140 molecules and platelet aggregation rate in the experimental group were significantly lower than those of the control group (p<0.05). Oral administration of rosuvastatin 1 week before PCI can significantly improve the blood lipid levels and hemorheological profiles, enhance endothelial function, reduce the PTX-3 level and the number of GMP-140 molecules, decrease the platelet aggregation rate, therefore improving prognosis in elderly patients with AMI undergoing PCI.